Dutch regulator orders Endorphina to block slots at unlicensed casinos

The Netherlands Gambling Authority (Kansspelautoriteit, or KSA) has issued a binding direction to Endorphina after finding that its slots remained playable on casino websites operating without a Dutch licence. The decision, dated 19 October 2026 and published on 2 November, concerns Endorphina Limited in Malta and Endorphina Ltd. in Cyprus.

The regulator's published notice says the companies had not taken adequate steps to prevent their games from appearing on websites that illegally target the Dutch market. KSA considers that failure to be facilitation of unlicensed gambling under Dutch law.

Repeated checks put distribution in focus

According to the reported inspection history, checks began in January 2026. Endorphina was informed of concerns in April, but inspectors found its slots again in June on sites including Qbet, LuckyGem and Justbit. A further inspection in late September reportedly identified games on eight more unlicensed websites.

Endorphina disputes any deliberate cooperation with illegal operators. Its explanation points to business-to-business intermediaries that distribute games beyond the studio's direct relationships. The company reportedly restricted access at problematic sites over the summer, but KSA concluded that the measures were insufficient.

That distinction matters: removing a game from one website does not necessarily stop it from reappearing through another distribution channel. The regulator is demanding effective controls over where the content can actually be launched by players in the Netherlands, rather than relying on a provider's stated intentions.

What happens after the deadline?

The October direction requires additional technical safeguards and a review of partner arrangements to prevent Dutch players from accessing Endorphina titles through unlicensed casinos. The deadline identified in the supplied account was 2 November 2026. That date has now passed, but the available notice does not establish whether Endorphina has complied.

KSA's notice says the decision can be challenged. The next substantive development will be confirmation of compliance or further regulatory action—not the mere expiry of the deadline.